Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
- Posted on April 30, 2026
- By CNBC
- 0 Views
- 1 min read
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
